|Gilead Sciences Inc -- USA Stock|| |
USD 79.74 0.23 0.29%
Chief Scientific Officer and Executive VP of RandD
Dr. Norbert W. Bischofberger, Ph.D., is no longer Executive Vice President Research and Development, Chief Scientific Officer of Gilead Sciences Inc effective April 30 2018
Age: 60 EVP Since 2007 Ph.D
Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.?s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside?s lab at Harvard University in Cambridge, Massachusetts.
Norbert Bischofberger Latest Insider Activity
The company has return on total asset (ROA)
of 14.15 %
which means that it generated profit of $14.15 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 23.3 %
meaning that it created $23.3 on every $100 dollars invested by stockholders.
The company currently holds 33.54 B in liabilities with Debt to Equity (D/E) ratio of 163.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences Inc has Current Ratio of 2.68 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and traded on NASDAQ. It employs 10000 people.Gilead Sciences Inc (GILD) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.